Aldeyra Therapeutics (NASDAQ:ALDX) vs. GelStat (OTCMKTS:GSAC) Critical Survey

Aldeyra Therapeutics (NASDAQ:ALDX) and GelStat (OTCMKTS:GSAC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings.

Earnings & Valuation

This table compares Aldeyra Therapeutics and GelStat”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85 million	($0.46)	-3.48
GelStat	N/A	N/A	N/A	N/A	N/A

Volatility and Risk

Aldeyra Therapeutics has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, GelStat has a beta of 1.86, suggesting that its share price is 86% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Aldeyra Therapeutics and GelStat, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1	2	1	0	2.00
GelStat	0	0	0	0	0.00

Aldeyra Therapeutics currently has a consensus target price of $5.50, suggesting a potential upside of 243.75%. Given Aldeyra Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Aldeyra Therapeutics is more favorable than GelStat.

Profitability

This table compares Aldeyra Therapeutics and GelStat’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
GelStat	N/A	N/A	N/A

Insider and Institutional Ownership

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 8.5% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 20.5% of GelStat shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The company’s clinical pipeline also includes ADX-2191, a dihydrofolate reductase inhibitor in Phase 3 testing for proliferative vitreoretinopathy, and ADX-1612, a chaperome inhibitor in Phase 2 testing for COVID-19 and ovarian cancer.

About GelStat

GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.